Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020092877 - MODULATION OF MITOCHONDRIAL BIOGENESIS BY INCREASE IN IRON SULFUR CLUSTER ACTIVITY

Publication Number WO/2020/092877
Publication Date 07.05.2020
International Application No. PCT/US2019/059345
International Filing Date 01.11.2019
IPC
G01N 33/00 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
G01N 33/50 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
G01N 33/90 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
90involving iron binding capacity of blood
Applicants
  • THE CHILDREN'S HOSPITAL OF PHILADELPHIA [US]/[US]
Inventors
  • RIVELLA, Stefano
  • LA, Ping
Agents
  • HIGHLANDER, Steven, L.
Priority Data
62/754,60602.11.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) MODULATION OF MITOCHONDRIAL BIOGENESIS BY INCREASE IN IRON SULFUR CLUSTER ACTIVITY
(FR) MODULATION DE LA BIOGENÈSE MITOCHONDRIALE PAR AUGMENTATION DE L'ACTIVITÉ DE GRAPPE FER-SOUFRE
Abstract
(EN)
The present disclosure relates to compositions and methods using the same to modulate mitochondrial biogenesis. The subject may suffer from a disease or disorder stemming from mitochondrial dysfunction, such as sideroblastic anemia. The agonist may be an AMPK protein or expression construct coding therefore, PCG- 1a protein or expression construct coding therefore, metformin, resveratrol or AICAR.
(FR)
La présente invention concerne des compositions et des procédés d'utilisation de celles-ci pour moduler la biogenèse mitochondriale. Le sujet peut souffrir d'une maladie ou d'un trouble issu d'un dysfonctionnement mitochondrial, tel que l'anémie sidéroblastique. L'agoniste peut être une protéine AMPK ou un hybride d'expression codant pour celle-ci, une protéine PCG-1a ou un hybride d'expression codant pour celle-ci, la metformine, le resvératrol ou l'AICAR.
Latest bibliographic data on file with the International Bureau